Pharmacoepigenetics in heart failure

Current Heart Failure Reports

Volumn 7, Issue 2, 2010, Pages 83-90

  Leach, Irene Mateo ^a   Van Der Harst, Pim ^a   De Boer, Rudolf A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

DNA methylation; Epigenetics; Heart failure; Histone modification; MicroRNA; Pharmacoepigenetics

Indexed keywords

BUTYRIC ACID; CASPASE 9; CD31 ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN D2; CYTOSINE; ESTROGEN RECEPTOR; GENOMIC DNA; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE INHIBITOR; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; LYSINE; MICRORNA; MYOCYTE ENHANCER FACTOR 2; MYOSIN HEAVY CHAIN BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREGNANE X RECEPTOR; PROLINE; RETINOIC ACID RECEPTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; THYROID TRANSCRIPTION FACTOR 1; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA;

ACETYLATION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; COLLAGEN SYNTHESIS; DISEASE PREDISPOSITION; DNA METHYLATION; DRUG RESPONSE; ENVIRONMENTAL FACTOR; EPIGENETICS; EUCHROMATIN; EUKARYOTE; GENE EXPRESSION; GENE MAPPING; GENE THERAPY; GENETIC TRANSCRIPTION; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HIGH THROUGHPUT SCREENING; HUMAN; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOSOME; PHARMACOGENETICS; PHENOTYPIC VARIATION; PROTEIN DNA INTERACTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; STRESS; SUMOYLATION; TREATMENT RESPONSE; UBIQUITINATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS;

DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; MICRORNAS; PHARMACOGENETICS;

EID: 77954594743     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-010-0011-y     Document Type: Review

References (58)

1. de Boer RA, van der Harst P, van Veldhuisen DJ, MP van den Berg: Pharmacogenetics in heart failure: promises and challenges. Expert Opin Pharmacother 2009, 10:1713-1725.
2. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
3. Codd V, Mangino M, van der Harst P, et al.: Common variants near TERC are associated with mean telomere length. Nat Genet 2010, 42:197-199.
4. Newton-Cheh C, Johnson T, Gateva V, et al.: Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41:666-676.
5. Dennis C: Epigenetics and disease: altered states. Nature 2003, 421:686-688.
6. Margulies KB, Bednarik DP, Dries DL: Genomics, transcriptional profiling, and heart failure. J Am Coll Cardiol 2009, 53:1752-1759.
7. Szyf M: Toward a discipline of pharmacoepigenomics. Curr Pharmacogenomics 2004, 2:357-377.
8. Peedicadyl J: Pharmacoepigenetics and pharmacoepigenomics. Pharmacogenomics 2008, 9:1785-1786.
9. Ingelman-Sundberg M, Sima SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Therapeut 2007, 116:496-526.
10. • Mano H: Epigenetic abnormalities in cardiac hypertrophy and heart failure. Environ Health Prev Med 2008, 13:25-29. This review offers a good overview of histone acetylation in relation to HF.
11. Bernstein BE, Meissner A, Lander ES: Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 2005, 120:169-181.
12. Zhang CL, McKinsey TA, Chang S, et al.: Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002 110:479-488.
13. Trivedi CM, Luo Y, Yin Z, et al.: Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007, 13:324-331.
14. Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 2004, 4:988-993.
15. Peaston AE, Whitelaw E: Epigenetics and phenotypic variation in mammals. Mamm Genome 2006, 17:365-374.
16. Klose RJ, Bird AP: Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006, 31:89-97.
17. Ball MP, Li JB, Gao Y, et al.: Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009, 27:361-368.
18. Kao YH, Chen YC, Cheng CC, et al.: Tumor necrosis factoralpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med 2010, 38:217-222.
19. • Movassagh M, Choy M-K, Goddard M, et al.: Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS One 2010, 5:e8564. This study reports genome-wide evidence for differential methylation between CVD patients and controls.
20. Schroen B, Heymans S: MicroRNAs and beyond: the heart reveals its treasures. Hypertension 2009, 54:1189-1194.
21. Silvestri P, Di Russo C, Rigattieri S, et al.: MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. Recent Pat Cardiovasc Drug Discov 2009, 4:109-118. This review offers a good compilation of evidence of miRNAs associated with HF.
22. Carè A, Catalucci D, Felicetti F, et al.: MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13:613-618.
23. Divakaran V, Mann DL: The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 2008, 103:1072-1083.
24. van Rooij E, Sutherland LB, Qi X, et al.: Control of stressdependent cardiac growth and gene expression by a micro- RNA. Science 2007, 316:575-579.
25. Zhao Y, Ransom JF, Li A, et al.: Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007, 129:303-317.
26. Thum T, Gross C, Fiedler J, et al.: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
27. Thum T, Galuppo P, Wolf C, et al.: MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007, 116:258-267.
28. Zorio E, Medina P, Rueda J, et al.: Insights into the role of microRNAs in cardiac diseases: from biological signalling to therapeutic targets. Cardiovasc Hematol Agents Med Chem 2009, 7:82-90.
29. Huang TH, Perry MR, Laux DE: Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999, 8:459-470.
30. Kaneda R, Toyota M, Yamashita Y, et al.: High-throughput screening of genome fragments bound to differentially acetylated histones. Genes Cells 2004, 9:1167-1174.
31. Kaneda R, Ueno S, Yamashita Y, et al.: Genome-wide screening for target regions of histone deacetylases in cardiomyocytes. Circ Res 2005, 97:210-218.
32. Soifer HS, Rossi JJ, Saetrom P: MicroRNAs in disease and potential therapeutic applications. Mol Ther 2007, 15:2070-2079.
33. Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447:433-440.
34. Pucéat M: Pharmacological approaches to regenerative strategies for the treatment of cardiovascular diseases. Curr Opin Pharmacol 2008, 8:189-192.
35. Gomez A, Ingelman-Sundberg M: Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 2009, 85:226-230.
36. Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
37. Gallo P, Latronico MV, Gallo P, et al.: Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res 2008, 80:416-424.
38. Sutherland JE, Costa M: Epigenetics and the environment. Ann NY Acad Sci 2003, 983:151-160.
39. Anway MD, Cupp AS, Uzumcu M, Skinner MK: Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 2005, 308:1466-1469.
40. Turan N, Katari S, Coutifaris C, Sapienza C: Explaining interindividual variability in phenotype: is epigenetics up to the challenge? Epigenetics 2010, 5:16-19.
41. Fraga MF, Ballestar E, Paz MF, et al.: Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005, 102:10604-10609.
42. The American Association for Cancer Research Human Epigenome Task Force and European Union, Network of Excellence, Scientific Advisory Board: Moving AHEAD with an international human epigenome project. Nature 2008, 454:711-715.
43. Mishra PK, Tyagi N, Kumar M, Tyagi SC: MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 2009, 13:778-789.
44. Chen JF, Murchison EP, Tang R, et al.: Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2008, 105:2111-2116.
45. Kwon C, Han Z, Olson EN, Srivastava D: MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci U S A 2005, 102:18986-18991.
46. Zhao Y, Samal E, Srivastava D: Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436:214-220.
47. Chen JF, Mandel EM, Thomson JM, et al.: The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006, 38:228-233.
48. Yang B, Lin H, Xiao J, et al.: The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007, 13:486-491.
49. Terentyev D, Belevych AE, Terentyeva R, et al.: miR-1 overexpression enhances Ca2+ release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56 {alpha} and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res 2009, 104:514-521.
50. Luo X, Lin H, Pan Z, et al.: Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem 2008, 283:20045-20052.
51. Luo X, Xiao J, Lin H, et al.: Transcriptional activation by stimulating protein 1 and post-transcriptional repression by muscle-specific microRNAs of IKs-encoding genes and potential implications in regional heterogeneity of their expressions. J Cell Physiol 2007, 212:358-367.
52. Ikeda S, He A, Kong SW, et al.: microRNA-1 negatively regulates expression of the hypertrophy-associated genes calmodulin and Mef2a. Mol Cell Biol 2009, 29:2193-2204.
53. Sayed D, Hong C, Chen IY, et al.: MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007, 100:416-424.
54. Xu C, Lu Y, Pan Z, et al.: The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007, 120:3045-3052.
55. Liu N, Bezprozvannaya S, Williams AH, et al.: microRNA- 133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008, 22:3242-3254.
56. Duisters RF, Tijsen AJ, Schroen B, et al.: miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009, 104:170-178.
57. Xiao J, Luo X, Lin H, et al.: MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 2007, 282:12363-12367.
58. Sucharov C, Bristow MR, Port JD: miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 2008, 45:185-192.